Effect of salicylic acid and diclofenac on the medium-chain and long-chain acyl-CoA formation in the liver and brain of mouse

Journal of Applied Toxicology

Volumn 29, Issue 5, 2009, Pages 435-445

  Kasuya, Fumiyo ^a   Kazumi, Maya ^b   Tatsuki, Takao ^b   Suzuki, Risa ^b  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b NONE

Author keywords

Acyl CoA esters; Brain; Fatty acid metabolism; Inhibition; Liver; Salicylic acid

Indexed keywords

ACYL COENZYME A; DICLOFENAC; LIGASE; LONG CHAIN ACYL COENZYME A; LONG CHAIN FATTY ACID COENZYME A LIGASE; MEDIUM CHAIN ACYL COENZYME A; MEDIUM CHAIN FATTY ACID COENZYME A LIGASE; SALICYLIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; DRUG EFFECT; ENZYME INHIBITION; FATTY ACID METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LIVER MITOCHONDRION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; TANDEM MASS SPECTROMETRY;

ACYL COENZYME A; ANIMALS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COENZYME A LIGASES; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS; FOOD DEPRIVATION; LIVER; MALE; MICE; MICE, INBRED STRAINS; MITOCHONDRIA; SALICYLIC ACID; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 67651177624     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1431     Document Type: Article

References (38)

1. Andresen BS, Dobrowolski SF, O'Reilly L, Muenzer J, McCandless SE, Frazier DM, Udvari S, Bross P, Knudsen I, Banas R, Chace DH, Engel P, Naylor EW, Gersen N. 2001. Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new prevalent mutation that results in mild MCAD deficiency. Am. J. Hum. Genet. 68: 1408-1418. (Pubitemid 32510616)
2. Becker CM, Harris RA. 1983. Influence of valproic acid on hepatic carbohydrate and lipid metabolism. Arch. Biochem. Biophys. 223: 381-392.
3. Boden G. 1997. Role of fatty acids in the pathogenesis of insulin residence and NIDDM. Diabetes 46: 3-10. (Pubitemid 27009941)
4. Brown RE, Foeman DT. 1982. The biochemistry of Reye's syndrome. Crit. Rev. Clin. Lab. Sci. 17: 247-297.
5. Chalkley SM, Hettriarachchi M, Chisholm DJ, Kraegen EW. 1998. Five-hour fatty acid elevation increases muscle lipids and impairs glycogen synthesis in the rat. Metabolism 47: 1121-1126.
6. Deschamps D, Fisch C, Fromenty B, Berson A, Claude Degott C, Pesssayre D. 1991. Inhibition by salicylic acid on the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye's syndrome. J. Pharmcol. Exp. Ther. 259: 894-903.
7. Farooqui AA, Horrocks LA. 1994. Excitotoxicity and neurological disorders: involvement of membrane phospholipids. Int. Rev. Neurobiol. 36: 267-323.
8. Farooqui AA, Horrocks LA, Farooqui T. 2000. Glycerophosholipids in brain: their metabolism, incorporation into membranes, function, and involvement in neurological disorders. Chem. Phys. Lipids 106: 1-29.
9. Fujino T, Takei YA, Sone H, Ioka RX, Kamataki A, Mgoori AK, Takahashi S, Sakai J, Yamamoto T. 2001. Molecular identification and characterization of two medium chain acyl-CoA synthetases, MACS1 and Sa gene product. J. Biol. Chem. 276: 35961-35966. (Pubitemid 37384405)
10. Gregersen N, Wintzensen H, Christensen SK, Christernsen MF, Brandt NJ. 1985. The acyl-CoA dehydrogenase deficiencies. Recent advances in the enzymatic characterization and understanding of the metabolic and pathophysiological disturbances in patients with acyl-CoA dehydrogenation deficiencies. Scand. J. Clin. Lab. Invest. Suppl. 6: 1270-1278.
11. Haketa A, Soma M, Nakayama T, Sato M, Kosuge K, Aoi N, Matsumoto K. 2004. Two medium-chain acyl-coenzyme A synthetase genes, SAH and MACS1, are associated with plasma high-density lipoprotein cholesterol levels, but they are not associated with essential hypertension. J. Hypertens. 22: 1903-1907. (Pubitemid 39341196)
12. Houston JB, Kenworthy KE. 2000. In vitro-in vivo scaling of CYP kinetic data is not consistent with the classical Michaelis-Menten model. Drug Metab. Dispos. 28: 246-254.
13. Itani SI, Rudeman NB, Schmeider F, Boden G. 2002. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and I κB-α. Diabetes 51: 2005-2011. (Pubitemid 34729001)
14. Kasuya F, Igarashi K, Fukui M, Nokihara K. 1996. Purification and characterization of a medium chain acyl-CoA synthetase. Drug Metab. Dispos. 24: 897-1883 (Pubitemid 26274746)
15. Kasuya F, Yamaoka Y, Ozawa E, Igarashi K, Fukui M. 2000. Difference of the liver and kidney in glycine conjugation of ortho-substituted benzoic acids. Chemico- Biol. Interact. 125: 39-50. (Pubitemid 30084783)
16. Kasuya F, Hiasa M, Kawai Y, Igarashi K, Fukui M. 2001. Inhibitory effects of quinolone antimicrobial and nonsteroidal anti-inflammatory drugs on a medium chain acyl-CoA synthetase. Biochem. Pharmacol. 62: 363-367. (Pubitemid 32575338)
17. Kasuya F, Ochi Y, Tatsuki T, Igarashi K. 2004. Analysis of medium-chain acyl-CoenzymeA esters in mouse tissues by liquid chromatography-electrospray ionization mass spectrometry. Anal. Biochem. 325: 196-205. (Pubitemid 38134356)
18. Kasuya F, Tatsuki T, Ohta M, Kawai Y, Igarashi K. 2006. Purification, characterization, and mass spectrometric sequencing of a medium chain acyl-CoA synthetase from mouse liver mitochondria and comparisons with the homologues of rat and bovine. Protein Expr. Purif. 47: 405-414. (Pubitemid 43729020)
19. Killenberg PG, Davidson ED, Webster LJ. 1971. Evidence for a medium chain fatty acid:coenzyme A ligase (adenosine monophosphate) that activates salicylate. Mol. Pharmacol. 7: 260-268.
20. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI. 2001. Prevention of fat-induced insulin resistance by salicylate. J. Clin. Invest. 10: 437-446. (Pubitemid 32730790)
21. Land WE. 1958. Metabolism of glycerolipides: a comparison of lecithin and triglyceride synthesis. J. Biol. Chem. 222: 193-214.
22. Lehmann B Von, Wan SH, Riegelman SH, Becker C. 1973. Renal contribution to overall metabolism of drugs IV: Biotransformation of salicylic acid to salicyluric acid in man. J. Pharm. Sci. 62: 1483-1487.
23. Lehnert W. 1993. Experiment with the 3-phenylpropionic acid loading test for diagnosis of medium chain acyl-CoA dehydrogenase deficiency (MCADD). Pediatr. Padol. 28: 9-12.
24. Linder I, Rubin D, Helwing U, Nitz I, Hampe J, Schreiber S, Schrezenmeir J, Doring F. 2006. The L513S polymorphism in medium-chain acyl-CoA synthetase 2 (MACS 2) is associated with risk factors of the metabolic syndrome in a Caucasian study population. Mol. Nutri. Food Res. 50: 270-274.
25. Mamunes P, DeVries GH, Miller CD, David RB. 1979. Fatty acid quantitation in Reye's syndrome. In Reye's Syndrome, Pollac JD (ed.). Grune and Stratton: New York; 217-235.
26. Mashek DG, Li LO, Coleman RA. 2006. Rat long-chain acyl-CoA synthetase mRNA, protein, and activity vary in tissue distribution and in response to diet. J. Lipid Res. 47: 2004-2010.
27. Möhlig M, Frendenberg M, Bobbert T, Ristow M, Rochlitz H, Weickert MO, Pfeiffer AFH, Spranger J. 2006. Acetylsalicylic acid improves lipid-induced insulin resistance in healthy men. J. Clin. Endcrinol. Metab. 91: 964-967. (Pubitemid 43357766)
28. Morishima T. 2004. Influenza-associated encephalopathy. Rinsho Shinkeigaku 44: 965-969.
29. Morishima T and the Collaborate Study Group on Influenza-associated Encephalopathy in Japan. Annual Report of the National Institute for Infectious Diseases of Japan, 2006. Japanese Ministry of Health and Welfare: Tokyo.
30. Morishima T, Togashi T, Yokota S, OkunoY, Miyazaki C, Tashiro M, Okabe N and the Collaborate Study Group on Influenza-associated Encephalopathy in Japan. 2002. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin. Infect. Dis. 35: 512-517.
31. Nielsen KB, Sorensen S, Cartegni L, Corydon TJ, Doktor TK, Schroeder LD, Reinert LS, Elpeleg O, Krainer AR, Gregersen N, Kjems J, Andresen BS. 2007. Seemingly nertral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer. Am. J. Hum. Genet. 80: 416-432. (Pubitemid 46310974)
32. Partin JC, Shubert WK, Partin JS. 1971. Mitochondrial ultrastructure in Reye's syndrome. New Engl. J. Med. 285: 1339-1343.
33. Van Meer G. 2005. Cellular lipidomics. EMBO 24: 3159-3165.
34. Ward MR. 1997. Reye's syndrome: an update. Nurse Pract. 22: 45-53.
35. Yoshida Y, Fujii M, Brown FR III, Singh I. 1988. Effect of salicylic acid on mitochondrial-peroxisomal fatty acid catabolism. Pediatr. Res. 23: 338-341. (Pubitemid 18079935)
36. Yoshida Y, Singh I, Singh AK, Techlenberg FW, Brown FR III, Darby CP. 1989. Reye's syndrome: rate of oxidation of fatty acids in leukocytes and serum levels of lipidperoxides. J. Exp. Pathol. 4: 133-139. (Pubitemid 19211900)
37. Yoshida Y, Wang S, Osame M. 1998. Aspirin induces short-chain free fatty acid accumulation in rats. Eur. J. Pharmcol. 349: 49-52. (Pubitemid 28270655)
38. Yuan M, Konstantopoulos N, Lee J, Hansen I, Li ZW, Karin M, Shoelson SE. 2001. Reversal of obesity- and diet-induced insulin resistance with salicylates of targeted disruption of Ikk-β. Science 293: 1673-1677. (Pubitemid 32807849)